Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.
Diamond B, Chahar D, Jain MD, Poos AM, Durante M, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan K, Jelinek T, Davies F, Figura NB, Morgan G, Mai E, Weisel KC, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Diamond B, et al. Among authors: maura f. bioRxiv [Preprint]. 2024 Nov 18:2024.11.15.623836. doi: 10.1101/2024.11.15.623836. bioRxiv. 2024. PMID: 39605649 Free PMC article. Preprint.
The cyclin-G associated kinase (GAK) is a novel mitotic kinase and therapeutic target in diffuse large B-cell lymphoma.
Lightfuss OB, Kumar P, Li L, Shastri T, Newsam AD, Manara P, Alaoui AY, Parets DEH, Younes PA, Chahar D, Arumov A, Coughlin CA, Williams IP, Fattakhov N, Martinez AB, Landgren O, Schurer SC, Lemmon V, Maura F, Bilbao D, Feng Y, Al-Ali H, Schatz JH. Lightfuss OB, et al. Among authors: maura f. bioRxiv [Preprint]. 2024 Oct 26:2024.10.21.619489. doi: 10.1101/2024.10.21.619489. bioRxiv. 2024. PMID: 39484514 Free PMC article. Preprint.
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14).
Tang H, Yan H, Shivaram S, Lehman S, Sharma N, Smadbeck J, Zepeda-Mendoza C, Tian S, Asmann Y, Vachon C, Gaspar Maia A, Keats J, Bergsagel PL, Fonseca R, Stewart AK, Hsu JS, Kandasamy RK, Pandey A, Kaddoura MA, Maura F, Mitra A, Rajkumar SV, Kumar SK, Elhaik E, Braggio E, Baughn LB. Tang H, et al. Among authors: maura f. Leukemia. 2025 Jan;39(1):42-50. doi: 10.1038/s41375-024-02363-y. Epub 2024 Oct 14. Leukemia. 2025. PMID: 39402215 Free PMC article.
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma.
Lee H, Durante M, Skerget S, Vishwamitra D, Benaoudia S, Ahn S, Poorebrahim M, Barakat E, Jung D, Leblay N, Ziccheddu B, Diamond B, Papadimitriou M, Cohen AD, Landgren O, Neri P, Maura F, Bahlis NJ. Lee H, et al. Among authors: maura f. Blood. 2024 Dec 19;144(25):2637-2651. doi: 10.1182/blood.2024026212. Blood. 2024. PMID: 39321344 Free article.
NRF2 translation block by inhibition of cap-dependent initiation sensitizes lymphoma cells to ferroptosis and CAR-T immunotherapy.
Manara P, Newsam AD, Saralamma VV, Russo MV, Martinez AB, Fattakhov N, Cunningham TA, Alaoui AY, Chahar D, Carbone AM, Lightfuss OB, Barroso AM, Hoffman KS, Maura F, Bilbao D, Schatz JH. Manara P, et al. Among authors: maura f. bioRxiv [Preprint]. 2024 Sep 13:2024.09.09.612133. doi: 10.1101/2024.09.09.612133. bioRxiv. 2024. PMID: 39314323 Free PMC article. Preprint.
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma.
Maura F, Kaddoura M, Poos AM, Baughn LB, Ziccheddu B, Bärtsch MA, Cirrincione A, Maclachlan K, Chojnacka M, Diamond B, Papadimitriou M, Blaney P, John L, Reichert P, Huhn S, Gagler D, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Rajkumar SV, Kumar S, Usmani S, Landgren O, Raab MS, Weinhold N. Maura F, et al. bioRxiv [Preprint]. 2024 Sep 4:2024.08.30.610457. doi: 10.1101/2024.08.30.610457. bioRxiv. 2024. PMID: 39282268 Free PMC article. Preprint.
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.
Ziccheddu B, Giannotta C, D'Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Ziccheddu B, et al. Among authors: maura f. Blood Cancer J. 2024 Jul 19;14(1):117. doi: 10.1038/s41408-024-01096-6. Blood Cancer J. 2024. PMID: 39030183 Free PMC article.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Bärtsch MA, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani S, Landgren O, Raab MS, Weinhold N, Maura F. Cirrincione AM, et al. Among authors: maura f. Blood. 2024 Aug 15;144(7):771-783. doi: 10.1182/blood.2024024299. Blood. 2024. PMID: 38728430
119 results